Company: PRGO
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001585364-25-000014
Chunk: 67

Company: PERRIGO Co plc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 67
---
 upper respiratory symptoms, including cough suppressants, expectorants, sinus and allergy relief.Nutrition(1)Infant formulas and nutritional beverages.Digestive HealthProducts such as antacids, anti-diarrheal, and anti-heartburn that relieve symptoms associated with digestive issues.Pain and Sleep-AidsProducts comprised of pain relievers, fever reducers and sleep-aids.Oral CareProducts used for oral care, including toothbrushes, toothbrush replacement heads, floss, flossers, whitening products and toothbrush covers.Healthy LifestyleProducts that help consumers live a healthy lifestyle such as smoking cessation, and well-being products.Skin CareProducts for the face and body such as dermatological care, scar management, lice treatment, and other products for various skin conditions.Women's HealthWomen's health products, including feminine hygiene and contraceptives.Vitamins, Minerals, and Supplements ("VMS")Vitamins, minerals, and supplements.Other(2)Rare Diseases Business and other miscellaneous self-care products.

(1) The Nutrition product category is exclusive to CSCA. During 2023 we exited the nutritional beverages product line.

(2) Rare Diseases Business within the Other product category is exclusive to CSCI. During 2024 we divested the Rare Diseases Business. Refer to Item 8. Note 3. 

In April 2022, we completed the acquisition of HRA Pharma for €1.8 billion, or approximately $1.9 billion based on exchange rates at the time of closing (refer to Item 8. Note 3 for transaction details). HRA Pharma operating results are reported within both our CSCA and CSCI segments. As a result of the acquisition, the Company made the following updates to its global reporting product categories described above:

•The creation of a new "Women's Health" reporting category, comprised of the women's health portfolio of HRA Pharma, including ellaOne® and Hana®, in addition to legacy Perrigo women's health products, including feminine hygiene and contraceptive products;

•The creation of a new "Skin Care" reporting category, comprised of Compeed®, Mederma®, and all of the products in the legacy Perrigo "Skincare and Personal Hygiene" category except for legacy Perrigo women's health products; and 

•The "Other" category includes the Rare Diseases Business acquired with HRA Pharma exclusive to the CSCI segment and other miscellaneous self-care products in CSCA. During 2024, we completed the sale of the Rare Diseases